Drug Type Trispecific antibody |
Synonyms CS-2006, CS2006, ND021 + [1] |
Target |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), albumin modulators(Serum albumin modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | 19 Aug 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | ES | 19 Aug 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | TW | 19 Aug 2020 | |
Colorectal Cancer | Phase 2 | US | 19 Aug 2020 | |
Colorectal Cancer | Phase 2 | ES | 19 Aug 2020 | |
Colorectal Cancer | Phase 2 | TW | 19 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 2 | US | 19 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 2 | ES | 19 Aug 2020 | |
Fallopian Tube Carcinoma | Phase 2 | TW | 19 Aug 2020 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 19 Aug 2020 |
NCT04442126 (SITC2022) Manual | Phase 1/2 | 26 | NM21–1480 | ujnfofehph(hwootsgbsw) = cpsqhbskkf yadfgacmlx (slifxbegdq ) View more | Positive | 01 Nov 2022 |